PRESS RELEASE
Biotest increases revenues by 9%
- EBIT increased to EUR 26.1 million
- Cash flow of EUR 46.9 million
- Guidance confirmed
Dreieich, 10 November 2016. In the first nine months of 2016, the Biotest Group generated revenues of EUR 455.6 million, after EUR 417.9 million in the same period of the previous year. This corresponds to an increase of 9.0%. The largest sales increase was generated in the USA at 43.5%. In addition to significantly increased sales of blood plasma, this reflects the positive effect of the cooperation agreement concluded with Kedrion Biopharma Inc., USA, in January 2016.
The EBIT amounted to EUR 26.1 million in the first nine months of 2016 compared to the previous year's figure of EUR -82.0 million. The EBIT margin amounted to 5.7%. The earnings after taxes in the amount of EUR -1.7 million (same period of the previous year: EUR -88.0 million) were reduced in the financial year by the one-time tax and interest expenses in connection with the agreement reached with the German tax authorities.
In the first nine months of 2016, the Biotest Group recorded a positive operating cash flow in the amount of EUR 46.9 million (same period of the previous year: EUR 34.2 million) despite the non-recurring tax payments.
The nine-month report is available on the company's website http://www.biotest.de/ww/en/pub/investor_relations/publications/quarterly_
reports.cfm. The presentation of today's conference for analysts and journalists is available for download from the website. After the conference, an
audio file will be available on the Biotest webpage.
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,400 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.
IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor.relations@biotest.com
PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.de
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart
Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.
2016-11-10 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
